These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35326677)

  • 1. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.
    Chan LL; Chan SL
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
    Liu TH; Shen YC; Cheng AL
    J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma?: A review of clinical trials.
    Eso Y; Taura K; Seno H
    Hepatol Res; 2022 Jan; 52(1):67-74. PubMed ID: 34520619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Brown ZJ; Gregory S; Hewitt DB; Iacono S; Choe J; Labiner HE; Pawlik TM
    Surg Oncol; 2022 Jun; 42():101748. PubMed ID: 35395582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Dyhl-Polk A; Mikkelsen MK; Ladekarl M; Nielsen DL
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208788
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Pinter M; Scheiner B; Peck-Radosavljevic M
    Gut; 2021 Jan; 70(1):204-214. PubMed ID: 32747413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in the Treatment of HCC.
    Donisi C; Puzzoni M; Ziranu P; Lai E; Mariani S; Saba G; Impera V; Dubois M; Persano M; Migliari M; Pretta A; Liscia N; Astara G; Scartozzi M
    Front Oncol; 2020; 10():601240. PubMed ID: 33585218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontline therapy for advanced hepatocellular carcinoma: an update.
    Akce M; El-Rayes BF; Bekaii-Saab TS
    Therap Adv Gastroenterol; 2022; 15():17562848221086126. PubMed ID: 35432597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
    Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives.
    Girardi DM; Pacífico JPM; Guedes de Amorim FPL; Dos Santos Fernandes G; Teixeira MC; Pereira AAL
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.